

B-2
20. (New) The method of claim 19, wherein the CED is into the striatum of the subject.

Attached hereto is a page marked VERSION WITH MARKINGS TO SHOW CHANGES MADE in claims.

II. REMARKS

The foregoing amendments are made to revise the title and amend the claims. Support of the amendments to the claims can be found throughout the specification, for example, on page 17, line 15 through page 18, line 18. Substantive examination of the newly-presented claims is respectfully requested. If the Examiner notes any further matters which the Examiner believes may be expedited by a telephone interview, the Examiner is requested to contact the undersigned.

Respectfully submitted,

Date: Aug 30, 2001

By: Dahna S. Pasternak
Dahna S. Pasternak
Registration No. 41,411

ROBINS & PASTERNAK LLP
90 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 325-7812
Facsimile: (650) 325-7823

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 1 through 8. Canceled.

9. (Amended) A method for treating [a neurodegenerative disease] Parkinson's Disease in a subject, said method comprising:

(a) providing a preparation comprising [recombinant adeno-associated virus (rAAV) virions, wherein said virions comprise] a viral vector comprising a nucleic acid sequence [that is expressible in transduced cells to provide a therapeutic effect in the subject] encoding aromatic amino acid decarboxylase (AADC), wherein said vector is produced *in vitro*; and

(b) delivering the preparation [to the CNS of the subject using convection-enhanced delivery (CED)] *in vivo*, to the brain of the subject, wherein said [virions] vectors transduce [neural] cells and the [nucleic acid sequence] AADC is expressed by the cells at levels that provide therapeutically effective levels of dopamine upon the oral administration of L-dopa [to provide a therapeutic effect in the subject suitable for treating said neurodegenerative disease].

Claims 10 through 17. Canceled.

18. (New) The method of claim 9, wherein the viral vector is a retroviral vector or an adenoviral vector.

19. (New) The method of claim 9, wherein the viral vector is delivered to the subject using convection-enhanced delivery (CED).

20. (New) The method of claim 19, wherein the CED is into the striatum of the subject.